Nuclear factor-κB expression as a novel marker of radioresistance in early-stage laryngeal cancer

✍ Scribed by Kenji Yoshida; Ryohei Sasaki; Hideki Nishimura; Yoshiaki Okamoto; Yoko Suzuki; Tetsuya Kawabe; Miki Saito; Naoki Otsuki; Yoshitake Hayashi; Toshinori Soejima; Kenichi Nibu; Kazuro Sugimura

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 482 KB
• Volume: 32
• Category: Article
• ISSN: 1043-3074
• DOI: 10.1002/hed.21239

✦ Synopsis

Abstract

Background.

The aim of this study was to evaluate the significance of nuclear factor‐kappa B (NF‐κB) expression as a marker of radioresistance in early‐stage laryngeal cancer.

Methods.

Thirty‐five patients with local recurrence and 70 case‐matched patients without local recurrence were entered in this study. NF‐κB expression was compared with Bcl‐2 and epidermal growth factor (EGF) receptor expression by immunohistochemistry, using pretreatment biopsy specimens. The prognostic value of NF‐κB was also evaluated. Twenty‐nine recurrent tumors were compared with pretreatment tumors.

Results.

NF‐κB expression in pretreatment tumors significantly correlated with local tumor control (p = .01), but bcl‐2 and EGF receptor expression did not. Only NF‐κB expression showed prognostic significance for local tumor control in both univariate and multivariate analyses (p = .008 and .04, respectively). NF‐κB expression was markedly enhanced in 23 of 29 (80%) recurrent tumors.

Conclusion.

NF‐κB expression may be a novel marker of radioresistance in early‐stage laryngeal cancer. © 2009 Wiley Periodicals, Inc. Head Neck, 2010